Thank you for your interest in our virtual round table on ESG, regulation and rebates in the health industry. This event will be held online on Wednesday 24 November 2021 from 15:00 to 16:00 CET, and again on Thursday 25 November 2021 from 09:00 to 10:00 CET.
Using environmental, social and governance (ESG) metrics to evaluate companies and countries on their progress towards sustainability has become a hot topic all around the world. Alongside these issues, the health sector is also facing major regulatory challenges.
We are delighted to invite you to our virtual Global Indirect Tax Health Industry Convention “Succeeding through uncertainty” on Thursday 6 May 2021 from 2pm to 6pm CEST. We will discuss the latest hot topics in the pharma, healthcare and life science industry from an indirect tax perspective and beyond.
The incredible pace of change in indirect taxes in the pharma, healthcare and life sciences industry shows no sign of slowing down. Digital transformation, changes in supply chains due to the pandemic, Brexit and complex developments in EU legislation are just some of the factors that are currently having a major impact on this industry and affecting almost every aspect of our business lives.
Discover PwC’s four cutting edge digital tax & regulatory solutions and how they can add value to your business, help you complying with new laws, stay up to date with upcoming changes in legislation and regulatory.
As the COVID-19 situation develops, tax and regulatory specialists within the pharmaceutical & life sciences industry are increasingly facing complex challenges. Efficient and pragmatic solutions have to be realised, with fewer resources, in line with the changing local legislation.
The exchange of information is the best practice in this industry to support and inspire you in your daily business.
I am pleased to invite you to our Webinar on Precision Medicine and Accurate Indirect Tax
During this digital presentation our panel of experts will give you an overview of possible indirect tax implications within the pharma sector. This panel consists of many tax specialists of the pharmaceutical sector and PwC’s international indirect tax experts. Experts, who are dedicated to the pharmaceutical industry.
I will use my time slot to discuss the implications for Switzerland including which countries will be covered.
You will have the opportunity to exchange your experiences and views on the issue with other international leaders.